Tirzepatide-Induced Biphasic Anaphylactic Reaction: A Case Report
- PMID: 38186543
- PMCID: PMC10771104
- DOI: 10.7759/cureus.50112
Tirzepatide-Induced Biphasic Anaphylactic Reaction: A Case Report
Abstract
Anaphylaxis is a rapid and severe reaction to a trigger that is characterized by skin, mucosal, and cardiorespiratory changes. A minority of patients exhibit a biphasic anaphylactic reaction (BAR). Tirzepatide is a dual incretin receptor analog approved for the treatment of type 2 diabetes mellitus (T2DM). Allergic reactions to tirzepatide were reported during clinical trials, but none were severe enough to be characterized as an anaphylactic reaction. We describe a case of a BAR to tirzepatide.
Keywords: biphasic anaphylactic reaction; gip-r; glp-1r; tirzepatide; type 2 diabetes mellitus.
Copyright © 2023, He et al.
Conflict of interest statement
The authors have declared that no competing interests exist.
Similar articles
-
Tirzepatide: A Novel, Once-weekly Dual GIP and GLP-1 Receptor Agonist for the Treatment of Type 2 Diabetes.touchREV Endocrinol. 2022 Jun;18(1):10-19. doi: 10.17925/EE.2022.18.1.10. Epub 2022 Jun 16. touchREV Endocrinol. 2022. PMID: 35949358 Free PMC article. Review.
-
The Role of Tirzepatide, Dual GIP and GLP-1 Receptor Agonist, in the Management of Type 2 Diabetes: The SURPASS Clinical Trials.Diabetes Ther. 2021 Jan;12(1):143-157. doi: 10.1007/s13300-020-00981-0. Epub 2020 Dec 15. Diabetes Ther. 2021. PMID: 33325008 Free PMC article. Review.
-
Tirzepatide - a dual GIP/GLP-1 receptor agonist - a new antidiabetic drug with potential metabolic activity in the treatment of type 2 diabetes.Endokrynol Pol. 2022;73(4):745-755. doi: 10.5603/EP.a2022.0029. Epub 2022 May 20. Endokrynol Pol. 2022. PMID: 35593668 Review.
-
Research Progress on the GIP/GLP-1 Receptor Coagonist Tirzepatide, a Rising Star in Type 2 Diabetes.J Diabetes Res. 2023 Apr 15;2023:5891532. doi: 10.1155/2023/5891532. eCollection 2023. J Diabetes Res. 2023. PMID: 37096236 Free PMC article. Review.
-
The catcher in the gut: Tirzepatide, a dual incretin analog for the treatment of type 2 diabetes mellitus and obesity.Metabol Open. 2022 Dec 5;16:100220. doi: 10.1016/j.metop.2022.100220. eCollection 2022 Dec. Metabol Open. 2022. PMID: 36530219 Free PMC article. Review.
Cited by
-
Benefit-Risk Assessment of GLP-1 Receptor Agonists: Implications for Dermatologists and Plastic Surgeons.Dermatol Ther (Heidelb). 2025 Sep 9. doi: 10.1007/s13555-025-01537-5. Online ahead of print. Dermatol Ther (Heidelb). 2025. PMID: 40924351 Review.
-
A retrospective observational study on case reports of adverse drug reactions (ADRs) to tirzepatide.Front Pharmacol. 2025 Jul 1;16:1608657. doi: 10.3389/fphar.2025.1608657. eCollection 2025. Front Pharmacol. 2025. PMID: 40667509 Free PMC article.
-
A Case Report of Systemic Allergic Reaction to the Dual Glucose-Dependent Insulinotropic Polypeptide/Glucagon-Like Peptide-1 Receptor Agonist Tirzepatide.Cureus. 2024 Jan 1;16(1):e51460. doi: 10.7759/cureus.51460. eCollection 2024 Jan. Cureus. 2024. PMID: 38298324 Free PMC article.
References
-
- Epidemiology of anaphylaxis: findings of the American College of Allergy, Asthma and Immunology Epidemiology of Anaphylaxis Working Group. Lieberman P, Camargo CA Jr, Bohlke K, Jick H, Miller RL, Sheikh A, Simons FE. Ann Allergy Asthma Immunol. 2006;97:596–602. - PubMed
-
- Making the GRADE in anaphylaxis management: toward recommendations integrating values, preferences, context, and shared decision making. Shaker MS, Oppenheimer J, Wallace DV, et al. Ann Allergy Asthma Immunol. 2020;124:526–535. - PubMed
-
- Biphasic anaphylaxis: a review of the literature and implications for emergency management. Pourmand A, Robinson C, Syed W, Mazer-Amirshahi M. Am J Emerg Med. 2018;36:1480–1485. - PubMed
Publication types
LinkOut - more resources
Full Text Sources